跳至主要内容
临床试验/NCT01006161
NCT01006161撤回2 期

Proof-of-Concept and Dose Range-Finding Study of SCH 527123 in Subjects With Severe Asthma

Merck Sharp & Dohme LLC0 个研究点开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
主要终点
Severe asthma exacerbations, pulmonary function test data, and a change in symptoms

研究概览

简要总结

Given the strong inhibition of SCH 527123 on neutrophil migration to sites of inflammation, there is a theoretical reason for its use in patients with severe asthma where neutrophils are thought to play a significant role in the pathophysiology of the disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject must have severe asthma, be at least 18 to less than or equal to 70 years of age, of either sex, and any race.

排除标准

  • Subject who has been diagnosed with COPD or any other clinically relevant lung disease, other than asthma (eg, cystic fibrosis, pulmonary fibrosis, bronchiectasis).

研究组 & 干预措施

Low dose SCH 527123

Experimental

干预措施: SCH 527123 (Drug)

Medium dose SCH 527123

Experimental

干预措施: SCH 527123 (Drug)

High dose SCH 527123

Experimental

干预措施: SCH 527123 (Drug)

Placebo

Placebo Comparator

干预措施: SCH 527123 (Drug)

结局指标

主要结局

Severe asthma exacerbations, pulmonary function test data, and a change in symptoms

时间窗: Measured over the duration of the trial.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Study of SCH 527123 in Subjects With Severe Asthma... | 临床试验